Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti (NASH)
NCT ID: NCT00681733
Last Updated: 2008-05-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2007-01-31
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. To compare the efficacy of pentoxifylline versus pioglitazone on the metabolic profile and liver histology of NASH patients.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Inclusion criteria
* Abdominal USG showing diffusely echogenic liver suggestive of fatty infiltration of liver.
* ALT \> 1.2 times the upper limit of normal for \> 6 months.(atleast three readings one month apart)
* Liver Biopsy showing steatosis affecting \>10% of hepatocytes with necroinflammatory activity, ballooning hepatocytes \&/ or fibrosis.
Exclusion criteria
* Alcohol intake of more than 20g/wk
* Evidence of viral/ autoimmune hepatitis
* PBC (Primary biliary cirrhosis)
* Biliary obstrution
* Wilson disease
* Haemchromatosis
* Decompensated cirrhosis
* Drug ingestion of the follwing drugs for a period of more than 4 weeks during past 6 weeks
* Amiodarone
* Methotrexate
* Perhexiline
* Glucocorticoids
* Estrogens
* Tamoxifen
* Nifedipine
* Diltiazem
* Tamoxifen
* DM Type I
STUDY DESIGN
The study will be divided into two parts Part A and Part B.
Part A
* A cross-sectional study of metabolic profile will be done at the enrollment with a detailed physical examination and laboratory investigations and certain specific tests for non-alcoholic steatohepatitis.
* At enrollment following characteristics will be included-
* Prior history of Diabetes, Hypertension, Dyslipidemia, Coronary artery disease.
* Age, sex, weight, height, BMI(body mass index), waist \& hip circumference.
* USG abdomen
* LFT
* Fasting glucose, post-prandial blood sugar/oral GTT(glucose tolerance test)
* Fasting insulin level
* Fasting C- peptide
* HOMA-IR (Homeostasis Model Assessment-insulin resistance)
* Fasting lipid profile
* Fasting TNF- α
* Fasting Adiponectin
* Fasting Leptin
* Liver biopsy
* Waist will be measured with soft tape on standing subjects midway between the lowest rib and iliac spine.
* BMI of every patient will be calculated.
* Lean patient will be defined as BMI of 18.5- 22.9 kg/m2
* Overweight as ≥ 23- 24.9 kg/m2
* Obese as ≥ 25 kg/m2
* Lean patient will be further categorized as
1. Normal waist circumference (\< 90cm for men, \< 80 cm for women)
2. Abnormal waist circumference (more than the above mentioned criteria)
* Insulin resistance will be calculated by HOMA-IR
* Fasting serum insulin (μIU/ ml) x Fasting serum glucose(mmol/l) ÷ 22.5 HOMA-IR \>2 will be taken as insulin resistance.
* TNF- α, adiponectin and leptin will be measured by ELISA method using standard kits.
* Liver biopsy will be analyzed by pathologist at the time of enrollment into the study. Histology reporting will be done by the method given by Brunt et al.23
Part B.
A Prospective Randomized Controlled Trial comparing efficacy of Pentoxyphylline versus Pioglitazone will be done.
A total of 40 NASH patients (lean and obese) will be enrolled. All will be advised dietary and exercise protocol. Twenty patients will be randomized to receive Pentoxifylline in a dose of 1200mg/day in 3 divided doses. Another twenty patients will receive Pioglitazone in a dose of 30 mg/day. The subjects will be randomly assigned to receive either pentoxifylline or pioglitazone (randomization will be computer-generated). Patients will be followed with liver biochemistry at monthly interval for initial 3 months and subsequently at 3 month interval. .Liver biopsy will be repeated at the end of 6 months of therapy. The pathologist will blinded to the drug administered to the NASH patients.
Adverse events associated with Pentoxifylline and pioglitazone will be inquired and recorded on follow-up visits. The known side-effects of Pentoxiphylline are nausea, headache, vomiting, dyspepsia, bloating, flushing, vertigo and gastroesophageal reflux and that of Pioglitazone are myalgia, weight gain and pedal edema.
END POINT OF THE STUDY
1. Repeat metabolic parameters and liver biopsy will be done at the end of 6 months.
2. Improvement by 50% or normalization of aminotransferase at the end of the study will be compared to the baseline.
3. Histology will be compared with the repeat liver biopsy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Pioglitazone
Pioglitazone
Pentoxifylline 1200mg/day in 3 divided doses. Pioglitazone 30 mg/day in single dose
Pioglitazone
30 mg OD
B
Pentoxifylline
Pentoxifylline
1200 mg/d
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pioglitazone
Pentoxifylline 1200mg/day in 3 divided doses. Pioglitazone 30 mg/day in single dose
Pioglitazone
30 mg OD
Pentoxifylline
1200 mg/d
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ALT \> 1.2 times the upper limit of normal for \> 6 months.(atleast three readings one month apart)
* Liver Biopsy showing steatosis affecting \>10% of hepatocytes with necroinflammatory activity, ballooning hepatocytes \&/ or fibrosis.
Exclusion Criteria
* Evidence of viral/ autoimmune hepatitis
* PBC (Primary biliary cirrhosis)
* Biliary obstrution
* Wilson disease
* Haemchromatosis
* Decompensated cirrhosis
* Drug ingestion of the follwing drugs for a period of more than 4 weeks during past 6 weeks - Amiodarone, Methotrexate, Perhexiline, Glucocorticoids, Estrogens, Tamoxifen, Nifedipine, Diltiazem, Tamoxifen.
* DM Type I
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Govind Ballabh Pant Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
G B Pant Hospital, New Delhi
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Barjesh Ch Sharma, MD, DM
Role: PRINCIPAL_INVESTIGATOR
G B Pant Hospital Hospital, New Delhi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dr. Barjesh Chander Sharma
New Delhi, New Delhi, India
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Barjesh Ch Sharma, MD, DM
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
drakchaudhary
Identifier Type: -
Identifier Source: secondary_id
drakchaudhary
Identifier Type: -
Identifier Source: org_study_id